Page 286 - TBE_Book_V2_2019

Chapter 12b: TBE in Finland

Overview of TBE in Finland

Table 1: Virus, vector, transmission of TBE in Finland

Viral subtypes, European and Siberian subtypes 5,9,20
distribution

12
Reservoir animals Microtus agrestis, Myodes glareolus
I. ricinus, I. persulcatus.
In average 1.6%;
11
Infected tick species (%) I. ricinus 0.2%, I. persulcatus 3.0%
In (suspected) endemic foci, TBEV RNA prevalence in field-collected ticks
has been reported to be about 0.1–3.0% 5,12,13

Table 2: TBE reporting and vaccine prevention in Finland

All patients with TBEV IgM antibodies are reported to National Infectious
Diseases Register at National Institute for Health and Welfare; a group of
Mandatory TBE reporting
experts interviews the patients and/or reviews the reports to confirm the
place of acquisition and that the cases are true TBE cases by definition

Other TBE surveillance Sentinel animals not systematically screened

14
Special clinical features Bi-phasic disease reported in about 30%

Available vaccines Encepur, Encepur Lapset (GSK), TicoVac and TicoVac Junior (Pfizer)

As part of the national vaccination program, the first 3 doses of vaccine
are provided free of charge to all permanent residents 3 years and older
in Åland. As of spring 2017, the national vaccination program has been
Vaccination expanded for 3-year-olds and older who spend a lot of time (live
recommendations and permanently or have a summer cottage) in certain other restricted highly
reimbursement endemic foci such as parts of Simo and Kemi, Parainen, archipelago of
Kotka, and Lohja.

15
Booster doses are not included in the vaccination program.

Vaccine uptake by age
16
group/risk group/general 9.3% for all populations
population
National Institute for Health and Welfare, THL,
Name, address/website
of TBE NRC Mannerheimintie 166, 00300 Helsinki
https://www.thl.fi

281